N/A N=30 Effects of Oropharyngeal Strengthening on Dysphagia in Patients Post-stroke
Stroke
Primary: Lingual Pressures (Changes in the One Repetition Maximum Isometric Lingual Pressures) — 83.3; 239.6; 129.8; 386.3 hPa
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=16 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
Chronic Allergic Conjunctivitis
Primary: Inflammation Change From Baseline to Day 6 — -1.2; -0.19 score on a scale
N/A N=240 Video Versus Conversational Contraceptive Counseling During Maternity Hospitalization
Contraceptive Usage · Contraception Behavior
Primary: Total Counseling Time — 16.8; 16.3 minutes
Phase 4 N=16 Effect of Aldosterone on Energy Starvation in Heart Failure
Heart Failure · Nonischemic Dilated Cardiomyopathy
Primary: Left Ventricular Work-metabolic Index (WMI) at Baseline — 7.4 (x10^6), mL x mm Hg/m^2
Phase 2 N=35 Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Biliary Cancer · Cholangiocarcinoma
Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants
N/A N=31 Profound Dermal and SubQ Cartridges for the Treatment of Cellulite
Cellulite
Primary: Improvement in Global Aesthetic Appearance of Cellulite in Treated Areas, as Assessed by Study Investigator Evaluations — 11; 7; 4; 16 Investigator Assessments
N/A N=190 Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass
Congenital Heart Disease · Disorder of Fetus or Newborn
Primary: Number of Participants With a Clinically Derived Composite Morbidity-mortality Outcome — 27; 40 Participants
Phase 3 N=363 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Colorectal Cancer
Primary: Overall Survival (OS) — 8.51; 8.87; 7.10 months — p=0.9871
Phase 3 N=506 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab…
Phase 3 N=1,037 Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
Post-ERCP Pancreatitis
Primary: Number of Participants Who Developed Post-ERCP Pancreatitis — 76; 65 Participants
Phase 2 N=21 Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Bone Cancer · Chondrosarcoma · Ewing's Sarcoma
Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds
N/A N=50 Teaching Use of Respiratory Inhalers (TURI)
Asthma · COPD
Primary: Number of Participants Misusing Metered-Dose Inhaler (MDI) Post Education Between Teach to Goal (TTG) and Brief Intervention (BI) — 3; 12 Participants
Phase 3 N=100 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers
Generalized Anxiety Disorder · Social Phobia · Separation Anxiety Disorder
Primary: PARS — 11.4; 14.7 units on a scale
Phase 2 N=42 Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
Chronic Obstructive Pulmonary Disease COPD
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.168; 0.267; 0.007 L — p=<0.001
Phase 2 N=88 A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Primary: Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year — 35; 40 Participants